Eli Lilly will present Phase 3 retatrutide and orforglipron data, tirzepatide cardiovascular findings, and eloraTZP results at EASD 2026.
Written By: Siddhi Bhadekar, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
Eli Lilly will present new clinical data from its cardiometabolic portfolio at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), including Phase 3 results for investigational retatrutide, Phase 3 findings for orforglipron, cardiovascular data for tirzepatide, and Phase 2 results for the investigational eloraTZP combination.
Retatrutide Shows Weight and A1C Improvements in Type 2 Diabetes
Retatrutide is an investigational once-weekly triple hormone receptor agonist that activates receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Lilly will present Phase 3 results from the TRIUMPH-2 study in adults with obesity or overweight and type 2 diabetes.
At 80 weeks, participants receiving retatrutide lost up to an average of 49.6 lb (22.5 kg), equivalent to 20.8% of body weight. Average A1C reductions reached 1.6%. These findings will be presented during an EASD-sponsored retatrutide symposium on September 30.
The broader Phase 3 program is evaluating retatrutide in obesity and overweight with weight-related medical conditions, type 2 diabetes, knee osteoarthritis, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease. Retatrutide remains investigational and is available only to participants in Lilly clinical trials.
Orforglipron Provides Phase 3 Cardiovascular Data
Foundayo (orforglipron) is a once-daily oral, non-peptide GLP-1 receptor agonist. Lilly will present Phase 3 results from the ACHIEVE type 2 diabetes program, including findings from ACHIEVE-4 in adults with type 2 diabetes and obesity or overweight who had increased cardiovascular risk.
In ACHIEVE-4, orforglipron demonstrated non-inferiority to insulin glargine for major adverse cardiovascular event (MACE) endpoints. The reported hazard ratio was 0.84 (95.0% CI, 0.59-1.20) for MACE-4 and 0.77 (95.0% CI, 0.52-1.13) for MACE-3.
Additional presentations will report time-to-goal analyses comparing orforglipron with dapagliflozin and oral semaglutide, as well as physical and psychosocial functioning outcomes from the ATTAIN-1 obesity study.
Tirzepatide Data Expand Cardiometabolic Evidence
Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist. Lilly will present SURPASS-CVOT findings in adults with type 2 diabetes and established cardiovascular disease.
Tirzepatide demonstrated non-inferiority versus dulaglutide, with an 8% lower observed risk of MACE-3 events and a hazard ratio of 0.92 (95.3% CI, 0.83-1.01). The study also showed greater reductions in A1C and body weight with tirzepatide.
Other presentations will examine beta-cell function and insulin sensitivity in early type 2 diabetes and glycemic control during Ramadan fasting.
EloraTZP Combines Amylin and GIP/GLP-1 Activity
EloraTZP combines eloralintide, an investigational selective amylin receptor agonist, with tirzepatide. Lilly will present Phase 2 results in adults with obesity or overweight and type 2 diabetes.
Earlier Phase 1 results showed that eloralintide 3 mg added to tirzepatide 5 mg produced 17% weight loss over 16 weeks, compared with 10% with tirzepatide 5 mg alone.
Eloralintide is being evaluated as a once-weekly selective amylin receptor agonist in Phase 3 studies for obesity and for obesity or overweight with or without type 2 diabetes.
EASD 2026 Will Feature Multiple Cardiometabolic Approaches
Lilly’s presentations at EASD 2026, scheduled for September 28 to October 2 in Milan, will cover several approaches to treating obesity and type 2 diabetes, including triple hormone receptor agonism, oral GLP-1 receptor activation, dual GIP/GLP-1 receptor agonism, and combination therapy involving amylin receptor activation.
The company will also host an industry symposium on September 28 covering treatment of obesity and type 2 diabetes from earlier stages of disease, oral therapies, and emerging mechanisms.
Reference
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health, Lilly, 15 September 2026
A Study of Retatrutide (LY3437943) in Participants with Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2), ClinicalTrials.gov ID NCT05929079
A Study of Tirzepatide (LY3298176) Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes (SURPASS-CVOT), ClinicalTrials.gov ID NCT04255433
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4), ClinicalTrials.gov ID NCT05803421
About the Writer
Siddhi Rajendra Bhadekar (Linkedin) is an M.Pharm professional with expertise in medical and scientific writing, literature review, publication writing, and evidence synthesis, supported by four peer-reviewed publications.
She brings working knowledge of ICH-GCP, MedDRA, pharmacovigilance, ADR/AE reporting, clinical data management, and regulatory documentation.
With experience across pharmaceutical R&D, Quality Control, and Quality Assurance, she combines scientific research skills with strong attention to accuracy and detail.
Her background in manuscript development, publication planning, and scientific communication enables her to translate complex healthcare information into clear, reliable content.